ASCO 2021, abstract
Isofol will present an abstract at the annual ASCO meeting between June 4 – June 8. Together with scientists from Sahlgrenska University Hospital and Precision for Medicine/QuartzBio (Geneva, Switzerland), we will present data about the regulation of 5-FU/folate-based treatment in colorectal cancer. MYC activation, a known transcriptional regulator of TYMS (the gene coding for TS), and one of the targets for the treatment, has been identified as a potentially relevant common upstream controller of a group of genes involved in 5-FU/folate efficacy. This relationship opens up for exploring further potential biomarker candidates as factors in 5-FU/Arfolitixorin efficacy and also combinations (including MYC-inhibitors).
Information about the presentation
Title: MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer
Authors: David A. Drubin, Anne-Katrin Hess, Natalie L. Catlett, Alessandro Di Cara, Yvonne Wettergren, Roger Tell
Abstract Number: e15512
Session title: Gastrointestinal Cancer—Colorectal and Anal